For example, given the high diagnostic accuracy of the combination of CSF α-synuclein and NfL, these two biomarkers could serve as an initial step to distinguish PSP and CBS from synucleinopathies such as PD, DLB, and MSA. This evidence concerns the gene SNCG and Lewy body dementia.